- Open Access
Effect of advanced glycosylation end products on apoptosis in human adipose tissue-derived stem cells in vitro
Cell & Biosciencevolume 5, Article number: 3 (2015)
Both apoptosis and caspase-3 activity in adipose tissue-derived stem cells play an important role in the therapeutic process of diabetes patients. The purpose of this study was to investigate the effect of advanced glycation end products-human serum albumin (AGE-HSA) on apoptosis in human adipose tissue-derived stem cells (ADSCs) and to characterize the signal transduction pathways activated by AGEs that are involved in apoptosis regulation.
AGE-HSA promoted apoptosis and caspase-3 activity in ADSCs. However, the effects of AGE-HSA were significantly attenuated by an inhibitor of p38 MAPK, but not by inhibitors of JNK MAPK or ERK MAPK. AGE-HSA also upregulated the expression of RAGE. Silencing of the RAGE gene inhibited AGE-HSA-induced apoptosis, and activation and expression of phosphorylated p38 MAPK.
These results suggest that AGE-HSA promote the apoptosis of ADSCs in vitro via a RAGE-dependent p38 MAPK pathway.
Advanced glycation end products (AGEs), which are produced by the posttranslational modification of proteins via non-enzymatic glycations, accumulate with age, and are abundantly increased in diabetic patients [1–3]. The formation and accumulation of AGEs are characteristic of tissues from patients with diabetes mellitus and have been strongly implicated in the pathogenesis of diabetic complications [4, 5]. AGEs are slowly and irreversibly formed on proteins that are exposed to carbonyl and substrate stress, especially under conditions of hyperglycemia, hyperlipidemia and/or oxidative stress . AGEs play an important role in the pathophysiological processes affecting patients with diabetes, Alzheimer's disease, and aging [2, 7, 8]. AGEs are known to cause adverse side effects on the growth of several cells, such as vascular endothelial cell and renal tubular epithelial cell [9–17]. A number of studies have suggested that AGEs mediate cell apoptosis and may play an important role in the pathogenesis of biophysical disorders [4, 6]. The elevated AGEs in diabetic patients could induce a number of pathological changes, such as promoting endothelial progenitor cell (EPC) and endothelial cell apoptosis [9, 18].
The receptor for advanced glycation end products (RAGE) is a signal transduction receptor, which senses a variety of signaling molecules including advanced glycation end products (AGEs). RAGE is a 35 kDa multiligand transmembrane receptor which belongs to the immunoglobulin gene superfamily . RAGE is widely localized in many cell types such as smooth muscle cells, hepatocytes, neurons, endothelial cells, and monocytes. Its expression can be abnormally up or downregulated in human diseases [20–22].RAGE is highly expressed in the bones of diabetic animal models compared to control animals . Recently, adipose tissue-derived stem cells (ADSCs) have been suggested as ideal for cell therapy because of their simple isolation techniques, easy expandability, low immunogenicity, and pluripotency [24, 25]. ADSC therapy could potentially have a large impact on the treatment of a wide variety of diseases, including diabetes and diabetic complications. However, increased apoptosis in stem cells has been demonstrated in a diabetic rat model . The deleterious effects of AGEs that involve RAGE expression were reported in stem cells .Nevertheless, there are few reports about the role of RAGE in ADSC therapy in complaint such as diabetes.
AGEs have been reported to activate serine-threonine protein kinases in the mitogen-activated protein kinase (MAPK) pathways. C jun N terminal kinase (JNK) and p38 MAPK are the two major subfamilies of MAPKs that participate in apoptosis. AGEs are known to induce osteoblast apoptosis via both JNK and p38 MAPK [15, 17, 27]. Despite ADSC administration was reported to improve healing in diabetic skin repair [28, 29], it remains unclear if AGEs could affect the apoptosis of ADSCs during the therapeutic process in diabetes patients. The purpose of the present study was to determine the effect of advanced glycation end products-human serum albumin (AGE-HSA) on ADSC apoptosis and to investigate the underlying molecular mechanism. The results of this study could lay a cellular basis for more effectively using ADSCs to treat diabetes and diabetic complications.
Characterization of ADSCs
ADSCs were isolated from human adipose tissue. As shown in Figure 1, adherent cells were seen after 1 d in culture (Figure 1A). After 3–4 d in culture, the cells had a short spindle shape (Figure 1B). Most of the cells exhibited fibroblast-like morphologies and were nearly confluent after 10 d in culture (Figure 1C). To characterize the cell surface marker profile of stem cells from human adipose tissue, cells from the third passage were analyzed by FACS. FACS showed that ADSCs expressed CD105 and CD90, but not CD34, CD14, CD45 or HLA-DR, consistent with previous reports  (Figure 1D). The cells were incubated with HSA (300 μg/ml) or AGE-HSA (300 μg/ml) for 24 h. Cells treated with AGE-HSA showed an obvious decrease in the percentage of cells expressing the stem cell-specific markers (CD105 and CD90) (Figure 1D and Table 1).
Effects of AGE-HSA on apoptosis and caspase-3 activity of ADSCs
The cells were incubated with HSA (300 μg/ml) or AGE-HSA at concentrations ranging from 50–500 μg/ml for 24 h. As shown in Figure 2, the cells treated with AGE-HSA showed an increase in apoptotic cell death compared to control cells (Figure 2A). Because caspase-3 is the principal effector caspase through which the mitochondrial and cytosolic pathways induce apoptosis, the levels of caspase-3 activity in each group were measured (Figure 2B). AGE-HSA significantly increased the caspase-3 activity in treated cells compared to control cells.
Effects of AGE-HSA on expression of RAGE of ADSCs
The effects of AGEs are mediated by interaction with or uptake by RAGE. To determine whether AGE-HSA might affect the expression of RAGE in ADSCs, the cells were incubated with HSA (300 μg/ml) or AGE-HSA (50–500 μg/ml) for 24 h, and then the expression of RAGE was determined by RT-PCR and western blot. As shown in Figure 3, cells treated with AGE-HSA showed an increase in expression of RAGE mRNA levels (Figure 3A and C) and protein levels (Figure 3B and C).
Role of MAPK pathway in AGE-HSA-promoted apoptosis of ADSCs
To determine whether the activation of MAPK was necessary for AGE-HSA-induced apoptosis in ADSCs, the cells were pre-treated for 60 min with pharmacological inhibitors of MAPK signaling pathways (U0126, SB203580, and SP600125). The cells were then treated with 300 μg/ml AGE-HSA for 24 h. Pre-treatment with the p38 inhibitor (SB203580) significantly reduced the AGE-HSA-mediated increase in apoptosis (Figure 4A) and caspase-3 activity (Figure 4B). Compared with the control group, SB203580 alone did not affect apoptosis (Figure 4A) and caspase-3 activity (Figure 4B). In contrast, U0126 (ERK) and SP600125 (JNK) had no effect on the level of apoptosis and caspase-3 activity induced by AGE-HSA. To further establish whether p38 MAPK phosphorylation was required for AGE-HSA induced apoptosis, cells were serum-starved and treated with AGE-HSA then analyzed for ERK1⁄2, p38, and JNK MAPK phosphorylation levels. p38 phosphorylation was rapidly induced in response to AGE-HSA. The peak response was obtained within 30 min and then phosphorylation declined to almost the basal level within 60 min. (Figure 4C-D). In contrast, AGE-HSA had no effect on activation of ERK1/2 and JNK MAPK (Figure 4E-H). These data indicated that the activation of p38 MAPK, but not the ERK1⁄2 and JNK pathways, was involved in AGE-HSA-induced apoptosis in ADSCs.
Effects of RAGE siRNA on apoptosis and caspase-3 activity of ADSCs induced by AGE-HSA
To test whether siRNA could silence RAGE expression, we treated ADSCs with three different RAGE siRNAs. After 24 h, the percentages of inhibition for RAGE mRNA expression were 87.3% (Target 1), 72.9% (Target 2), and 90.9% (Target 3) for each of the different siRNAs (Figure 5B) RAGE mRNA downregulation was paralleled by a decrease in RAGE protein abundance. The percentages of inhibition for RAGE protein expression were 71.5% (Target 1), 81.7% (Target 2), and 89.1% (Target 3) at 24 h (Figure 5C). Because Target 3 appeared to be the most effective at inhibiting RAGE mRNA and protein expression, this siRNA was used for subsequent experiments.
We next evaluated whether silencing the RAGE gene might affect the level of apoptosis and caspase-3 activity of ADSCs induced by AGE-HSA. The mock-, control siRNA- or RAGE siRNA-transfected ADSCs were supplemented with either HSA or AGE-HSA (300 μg/ml) for 24 h. The level of apoptosis and caspase-3 activity was then quantified by ELISA. No significant differences were observed in the level of apoptosis or caspase-3 activity between the three groups in the cells treated with HSA. However, after incubation with AGE-HSA, the level of apoptosis (Figure 6A) and caspase-3 activity (Figure 6B) was partly inhibited by the RAGE-specific siRNA compared to the control siRNA. In the groups that were mock transfected or transfected with control siRNA, the levels of apoptosis and caspase-3 activity were not significantly different.
Effects of RAGE siRNA on p38 MAPK activation of ADSCs induced by AGE-HSA
To determine whether silencing the RAGE gene affected AGE-HSA mediated signaling downstream in the MAPK pathway, we evaluated p38 MAPK phosphorylation in the mock-, control siRNA- RAGE siRNA-, or RAGE siRNA + PCDNA3.1-RAGE expression construct (rescue) transfected ADSCs. The cells were supplemented with either HSA or AGE-HSA (300 μg/ml) for 24 h. Then, p38 MAPK phosphorylation and RAGE was quantified by Western blot analysis. No significant differences in the phosphorylation of p38 were observed between the three groups treated with HSA. However, after incubation with AGE-HSA, the phosphorylation of p38 was partly inhibited by the RAGE-specific siRNA compared with the non-binding control siRNA (Figure 6C-D). In groups that were mock transfected, transfected with control siRNA or in rescue condition, the p38 phosphorylation was not significantly different. Moreover, the expression of RAGE in these cells was also quantified by Western blot analysis (Figure 6E-F).
ADSCs have similar features to MSCs from other tissues such as a high proliferative rate and the potential to differentiate into diverse cell lineages of both mesodermal and nonmesodermal origin. Moreover, ADSCs are also abundant and easy to sample in adults, which could potentially allow them to be used for autologous transplantation [24–27]. Recent preclinical studies have shown the beneficial effect of ADSC administration for treating a wide variety of diseases, including in animal models of diabetes [28–31]. However, the expansion and differentiation of ADSCs in vitro could be affected by many factors including: growth factors, chemical signals, and seeding density that may all indirectly influence the subsequent therapeutic effects. In addition, the culture media components may influence stem cell proliferation replicative senescence, and apoptosis .
AGEs have been shown to stimulate the activation of MAPK cascades in different cell types [11–15]. Furthermore, MAPK signals are robustly activated in a variety of disease states and have been implicated in mediating apoptotic responses. AGEs have been reported to induce apoptosis in osteoblasts and fibroblasts via the JNK and p38 MAPK pathways [16, 17]. Based on these data, we hypothesized that AGE-HSA induced apoptosis in ADSCs could involve the MAPK pathways. Thus, we investigated the role of p38, ERK1⁄2, and JNK MAPK signaling in apoptosis and caspase-3 activity in ADSCs. Our data showed that AGE-HSA induced the phosphorylation of p38 MAPK, and that pretreatment with SB203580 inhibited AGE-HSA-induced apoptosis, suggesting that p38 MAPK potentially played an important role in regulating AGE-HSA induced apoptosis. In contrast, specific inhibitors of ERK and JNK, had no effect on the level of apoptosis in ADSCs.
RAGE is the best-characterized AGE receptor and is responsible for most of the damaging effects of AGEs [32–34]. Here, we demonstrated that ADSCs expressed RAGE protein and that the incubation of ADSCs with AGE-HSA resulted in significant upregulation of RAGE expression. Our results were consistent with Kume et al., who showed that MSCs expressed RAGE, and that its induction was stimulated by AGE-2 and AGE-3. Previous reports have shown that downstream apoptotic signals from RAGE can be mediated through the p38 MAPK and JNK pathways. In osteoblast cells CML-collagen-induced apoptosis, and therefore impaired bone formation, was reduced by p38 MAPK (45%) or JNK (59%) inhibitors, and the effect was additive as treatment with both kinase inhibitors caused a 90% reduction in cell apoptosis . Furthermore, AGE-mediated apoptosis in endothelial progenitor cells was shown to be significantly inhibited by anti-RAGE neutralizing antibody . To confirm the involvement of RAGE in mediating apoptosis by AGE-HSA, we used an siRNA approach to block RAGE in ADSCs. We found that siRNAs significantly suppressed AGE-HSA stimulated apoptosis. These results demonstrate the critical role of RAGE in mediating stem cell survival and highlight the importance of the RAGE ligand axis in ADSC therapy for diabetes. Furthermore, knocking down RAGE expression resulted in an obvious decrease in the level of p38 MAPK phosphorylation stimulated by AGE-HSA. This suggests that the activation of p38 MAPK stimulated by AGE-HSA might be RAGE dependent.
The present study demonstrates AGEs increased apoptosis of ADSCs via a RAGE-p38 MAPK-mediated pathway. Together with other related studies, these results could provide insights about how to block the adverse effects of AGEs on ADSCs, and could lead to improvements in the clinical application of ADSCs.
Materials and methods
This study was conducted in accordance with the ethical standards laid out in the Declaration of Helsinki (1975) and was approved by the Institutional Ethics Committee at China Medical University. Adipose tissue samples were obtained with informed consent from patients at Shengjing Hospital. The ADSCs were isolated and harvested as previously described . Briefly, adipose tissues were digested with type I collagenase (Roche Diagnostic, Mannheim, Germany) under gentle agitation at 37°C for 30 min. The enzyme activity was neutralized with FBS, and the suspensions were centrifuged at 300 g for 10 min to remove floating mature adipocytes. The cells were seeded into DMEM medium supplemented with 10% FBS. The cultures were maintained at 37°C in a 5% CO2 incubator. After 48 h, non-adherent cells were removed, and adherent cells were washed 3 times with phosphate-buffered saline (PBS). The medium was changed every 3 days, and the cells were subcultured when the monolayer of adherent cells reached confluence. ADSCs were used in experiments between passages 3–6.
Flow cytometry was used to detect cell surface markers on the cultured cells. The cells were trypsinized with 0.05% trypsin-EDTA, collected in regular mesenchymal cell media, and centrifuged for 5 min at 800 g at 4°C. Then, the cells were resuspended in PBS containing 1% bovine serum albumin at 106 cells/ml and incubated with monoclonal PE-conjugated antibodies for CD45, CD34, CD14, and HLA-DR; an FITC-conjugated antibodies for CD90 and CD105 or matching isotype controls (all from Becton-Dickinson, USA) for 45 min on ice. The cells were subsequently washed with PBS, fixed with 1% formaldehyde, and analyzed by flow cytometry. A minimum of 10,000 cell events per sample were acquired on a FACSCalibur flow cytometer.
Treatment with specific inhibitors
For some experiments, specific inhibitors were added to cells and incubated for 60 min before treatment with AGE-HSA (St. Louis, USA). The ERK inhibitor (U0126), JNK inhibitor (SB203580), and p38 inhibitor (SP600125) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Small interfering RNA transfection and contransfection
Cells were plated in 6 cm2 dishes (4 × 105 cells per dish). The cells were grown to 70% confluence and transfected with siRNA complexes or transfection reagents alone (mock transfection) using Lipofectamine 2000 (Gibco BRL) according to manufacturer’s instructions as previously described . A scramble siRNA duplex (fluorescein) was used as a negative control. In the rescue condition, subjects were cotransfected with siRNA and a PCDNA3.1-RAGE expression construct.The final concentration of siRNA used for each transfection was 50 nM.
For the apoptosis assays, cells were plated in 96-well plates at a density of 2.0 × 104 cells per well. They were incubated until they were approximately 80% confluent, and then they were changed to the assay medium. To induce apoptosis, ADSCs were exposed to HSA (300 μg/ml) or AGE-HSA at various concentrations (50-500 μg/ml) for 24 h. To determine the role of different signaling pathways in apoptosis, ADSCs were pretreated with MAPK inhibitors U0126(50 μmol/l), SB203580(10 μmol/l), SP600125 (50 μmol/l), or RAGE siRNA for 60 min where indicated, and then apoptosis was induced with 300 μg/ml AGE for 24 h. The level of apoptosis was determined using the Cell Death Detection ELISAPLUS kit (Roche Applied Science, Indianapolis, IN), which detects cytoplasmic histone-associated DNA fragments, according to the manufacturer’s instructions as previously reported . Absorbance was measured at 405 nm with a PowerWave 2 multiplate reader spectrophotometer.
Caspase-3 activity assay
As a marker of apoptosis, Caspase-3 activation was assessed using the Caspase-Glo3/7 Assays (Promega, Madison, USA). Cells were plated in 96-well plates at a density of 2.0 × 104 cells per well and incubated for 24 h. The cells were treated as described above in the apoptosis assay. After the cells were treated, 60 μl of the supernatant was aliquoted from each well to a new 96-well plate. An equal volume of Caspase-Glo 3/7 reagents were added, and then incubated for 1 h at room temperature before measuring the luminescence of the samples.
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR)
RT-PCR was performed as previously described . Briefly, total RNA was extracted from each sample using Trizol reagent (Invitrogen) according to the manufacturer’s instructions, and dissolved in DEPC-treated water. The quality of the isolated RNA was checked by agarose gel electrophoresis, and RNA concentration was determined by measuring optical density at 260 and 280 nm. Total RNA (2 μg) in a final volume of 40 μl was subjected to reverse transcription. cDNA synthesis was carried out using random hexamer primers and MMLV reverse transcriptase, under the conditions recommended by the manufacturer (Invitrogen). Specific primers were manually designed using Gene Runner software (Hastings Software, Inc.). Sequences of primers and PCR conditions used are shown in Table 2.
ADSCs were lysed with isogen reagent (Nippon Gene, Tokyo, Japan) for RNA extraction. Total RNAs were reverse transcribed with SuperScript II Reverse Transcriptase (Takara) into cDNA. The full length human RAGE CDS sequence was amplified by PCR and specific primers with kpn1 restriction sites were designed according to sequence number NM_001206954.1 on (http://www.ncbi.nlm.nih.gov ). Full length RAGE was inserted into a pCDNA3.1 vector to construct a mammalian expression plasmid (PCDNA3.1-RAGE). Successful insertion was confirmed by sequencing.
Western blot analysis
Protein was isolated from harvested cells using mechanical disruption and the Mammalian Cell Lysis Kit (Sigma-Aldrich, St Louis, MO) according to the manufacturer’s instruction. The proteins were separated on 1 mm NuPage Novex 10% Bis-Tris gels using the NuPage MOPS SDS Buffer Kit (Life Technologies, Carlsbad, CA, USA) followed by electrotransfer to 0.2 mm nitrocellulose membranes (Pall, Port Washington, WI, USA). Nonspecific binding sites were blocked with 5% bovine serum albumin in PBS for 1 hour at room temperature (RT). Membranes were then incubated with diluted primary antibody (1:1000; Cell Signaling Technology, Inc.) at 4°C overnight. Following three washes with PBS containing 0.5% Tween-20, membranes were incubated with diluted secondary antibody (GE Healthcare, Buckinghamshire, UK) at RT for two hours. The signal was visualized with an enhanced chemiluminescent reagent (Amersham Biosciences, Piscataway, NJ). For the protein loading control, blots were stripped and stained for GAPDH using an anti-GAPDH antibody (1:2000, AbCam, Cambridge, MA).
Statistical analysis was performed using SPSS version 19.0 software. Data are presented as means ± standard deviation (SD). Univariate comparisons of the means were performed using the Student’s t test with a significance threshold of p < 0.05. The data shown in the figures are representative of three independent experiments.
Advanced glycation end products-human serum albumin
Adipose tissue-derived stem cells
Receptor for advanced glycation end products
Mitogen-activated protein kinase
Endothelial progenitor cell
C jun N terminal kinase
Reverse transcription-polymerase chain reaction.
Del Turco S, Basta G: An update on advanced glycation endproducts and atherosclerosis. Biofactors 2012, 38:266–74. 10.1002/biof.1018
Vlassara H, Uribarri J: Advanced Glycation End Products (AGE) and diabetes: cause, effect, or both? Curr Diab Rep 2014, 14:1–10.
Forbes JM, Sourris KC, de Courten MP, Dougherty SL, Chand V, Lyons JG, et al.: Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects. Amino Acids 2014, 46:321–6. 10.1007/s00726-013-1542-9
Kim S, Kwon J: COMP-Ang1 inhibits apoptosis as well as improves the attenuated osteogenic differentiation of mesenchymal stem cells induced by advanced glycation end products. Biochim Biophys Acta 1830, 2013:4928–34.
Ishibashi Y, Yamagishi S, Matsui T, Ohta K, Tanoue R, Takeuchi M, et al.: Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism 2012, 61:1067–72. 10.1016/j.metabol.2012.01.006
Barlovic DP, Thomas MC, Jandeleit-Dahm K: Cardiovascular Disease: Whats All the AGE/RAGE About? Cardiovasc Haematological Dis-Drug Targets 2010, 10:7–15. 10.2174/187152910790780050
Monnier VM, Sun W, Sell DR, Fan X, Nemet I, Genuth S: Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications. Clin Chem Lab Med 2014, 52:21–32.
Vlassara H, Striker GE: Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin North Am 2013, 42:697–719. 10.1016/j.ecl.2013.07.005
Pan Y, Liang H, Liu H, Li D, Chen X, Li L, et al.: Platelet-secreted MicroRNA-223 promotes endothelial cell apoptosis induced by advanced glycation End products via targeting the insulin-like growth factor 1 receptor. J Immunol 2014, 192:437–46. 10.4049/jimmunol.1301790
Shi L, Yu X, Yang H, Wu X: Advanced glycation end products induce human corneal epithelial cells apoptosis through generation of reactive oxygen species and activation of jnk and p38 mapk pathways. PLoS One 2013, 8:e66781. 10.1371/journal.pone.0066781
Lien SC, Chang SF, Lee PL, Wei SY, Chang MD, Chang JY, et al.: Mechanical regulation of cancer cell apoptosis and autophagy: Roles of bone morphogenetic protein receptor, Smad1/5, and p38 MAPK. Biochim Biophys Acta 2013, 1833:3124–33. 10.1016/j.bbamcr.2013.08.023
Zhang W, Lan Y, Huang Q, Hua Z: Galangin induces B16F10 melanoma cell apoptosis via mitochondrial pathway and sustained activation of p38 MAPK. Cytotechnology 2013, 65:447–55. 10.1007/s10616-012-9499-1
Yin Y, Liu W, Ji G, Dai Y: The essential role of p38 MAPK in mediating the interplay of oxLDL and IL-10 in regulating endothelial cell apoptosis. Eur J Cell Biol 2013, 92:150–9. 10.1016/j.ejcb.2013.01.001
Zheng F, Tang Q, Wu J, Zhao S, Liang Z, Li L, et al.: p38α MAPK-mediated induction and interaction of FOXO3a and p53 contribute to the inhibited-growth and induced-apoptosis of human lung adenocarcinoma cells by berberine. J Exp Clin Cancer Res 2014, 33:1–12. 10.1186/1756-9966-33-1
Hsu WH, Hsieh YS, Kuo HC, Teng CY, Huang HI, Wang CJ, et al.: Berberine induces apoptosis in SW620 human colonic carcinoma cells through generation of reactive oxygen species and activation of JNK/p38 MAPK and FasL. Arch Toxicol 2007, 81:719–28. 10.1007/s00204-006-0169-y
Alikhani M, Maclellan CM, Raptis M, Vora S, Trackman PC, Graves DT: Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. Am J Physiol Cell Physiol 2007, 292:C850–6.
Gangoiti MV, Cortizo AM, Arnol V, Felice JI, McCarthy AD: Opposing effects of bisphosphonates and advanced glycation end-products on osteoblastic cells. Eur J Pharmacol 2008, 600:140–7. 10.1016/j.ejphar.2008.10.031
Sun C, Liang C, Ren Y, Zhen Y, He Z, Wang H, et al.: Advanced glycation end products depress function of endothelial progenitor cells via p38 and ERK 1/2 mitogen-activated protein kinase pathways. Basic Res Cardiol 2009, 104:42–9. 10.1007/s00395-008-0738-8
Yao D, Brownlee M: Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes 2010, 59:249–55. 10.2337/db09-0801
Yamagishi S: Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol 2011, 46:217–24. 10.1016/j.exger.2010.11.007
Xie J, Méndez JD, Méndez-Valenzuela V, Aguilar-Hernández MM: Cellular signalling of the receptor for advanced glycation end products (RAGE). Cell Signal 2013, 25:2185–97. 10.1016/j.cellsig.2013.06.013
Chen J, Song M, Yu S, Gao P, Yu Y, Wang H, et al.: Advanced glycation endproducts alter functions and promote apoptosis in endothelial progenitor cells through receptor for advanced glycation endproducts mediate overpression of cell oxidant stress. Mol Cell Biochem 2010, 335:137–46. 10.1007/s11010-009-0250-y
Sun N, Yang L, Li Y, Zhang H, Chen H, Liu D, et al.: Effect of advanced oxidation protein products on the proliferation and osteogenic differentiation of rat mesenchymal stem cells. Int J Mol Med 2013, 32:485–91.
Liu X, Wang Z, Wang R, Zhao F, Shi P, Jiang Y, et al.: Direct comparison of the potency of human mesenchymal stem cells derived from amnion tissue, bone marrow and adipose tissue at inducing dermal fibroblast responses to cutaneous wounds. Int J Mol Med 2013, 31:407–15.
Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J: Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev 2012, 21:2724–52. 10.1089/scd.2011.0722
Saki N, Jalalifar MA, Soleimani M, Hajizamani S, Rahim F: Adverse effect of high glucose concentration on stem cell therapy. Int J Hematol Oncol Stem Cell Res 2013, 7:34–40.
Alikhani M, Alikhani Z, Boyd C, MacLellan CM, Raptis M, Liu R, et al.: Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007, 40:345–53. 10.1016/j.bone.2006.09.011
Cianfarani F, Toietta G, Di Rocco G, Cesareo E, Zambruno G, Odorisio T: Diabetes impairs adipose tissue–derived stem cell function and efficiency in promoting wound healing. Wound Repair Regen 2013, 21:545–53. 10.1111/wrr.12051
Locke M, Feisst V, Dunbar P: Human adipose-derived stem cells: separating promise from clinical need. Stem Cells 2011, 29:404–11. 10.1002/stem.593
Jin HJ, Bae YK, Kim M, Kwon SJ, Jeon HB, Choi SJ, et al.: Comparative analysis of human mesenchymal stem cells from bone marrow, adipose tissue, and umbilical cord blood as sources of cell therapy. Int J Mol Sci 2013, 14:17986–8001. 10.3390/ijms140917986
Al-Nbaheen M, Vishnubalaji R, Ali D, Bouslimi A, Al-Jassir F, Megges M, et al.: Human stromal (mesenchymal) stem cells from bone marrow, adipose tissue and skin exhibit differences in molecular phenotype and differentiation potential. Stem Cell Rev Rep 2013, 9:32–43. 10.1007/s12015-012-9365-8
Stirban A, Gawlowski T, Roden M: Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms. Mol Metab 2013, 3:94–108.
Ramasamy R, Vannucci SJ, Yan SS, Herold K, Yan SF, Schmidt AM: Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 2005, 15:16R-28. 10.1093/glycob/cwi053
Zong H, Ward M, Stitt AW: AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep 2011, 11:244–52. 10.1007/s11892-011-0198-7
Chen Q, Dong L, Wang L, Kang L, Xu B: Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Bioche Biopphy Res Commun 2009, 381:192–7. 10.1016/j.bbrc.2009.02.040
This study was supported by the National Basic Science and Development Program (973 Program 2012CB518103), National Natural Science Foundation (81370883), Liaoning Province Science (2011225020, 2012225080, 2012225014, 201322503) and Technology Plan and the Shenyang Science and Technology Program (F11-262-9-01, F11-262-9-52).
The authors declare that they have no competing interests.
ZW was responsible for designing of the study and critical review of manuscript. HQL and DBZ coordinated the study and performed statistical analyses. DBZ and XYL were involved in cell biology experiment and writing parts of the manuscript. ZWJ and HQL were responsible for critical review of manuscript. All authors read and approved the final version of manuscript.
About this article
- Human adipose tissue-derived stem cells
- Advanced glycation end products
- Mitogen-activated protein kinase
- Receptor for advanced glycation end products